Home › Companies › ARTV

Artiva Biotherapeutics, Inc.

ARTV Rare disease Lead: Phase 2 5 Biotech Distilled articles ↓

Dermatology Immunology Oncology Renal Cell

Most recent annual filing: 2026-03-15

Pipeline (16 active programs)

AlloNK

AB-101

Cell Target: CD20, CD19

Rheumatoid Arthritis Phase 1 GC Cell
Sjögren's Disease Phase 2 GC Cell
Systemic Sclerosis Phase 2 GC Cell
Idiopathic Inflammatory Myopathies Phase 2 GC Cell
Systemic Lupus Erythematosus Phase 1 GC Cell
Lupus Nephritis Phase 1 GC Cell
Pemphigus Vulgaris Phase 1 Integral Rheumatology & Immunology Specialists
ANCA-Associated Vasculitis Phase 1 Integral Rheumatology & Immunology Specialists

AB-201

Cell Target: HER2

Breast Cancer GC Cell
Gastric Cancer GC Cell
Bladder Cancer GC Cell
Undisclosed indication GC Cell

AB-205

Cell Target: CD5

T-Cell Lymphoma GC Cell
T-Cell Acute Lymphoblastic Leukemia GC Cell
Undisclosed indication GC Cell

AB-202

Undisclosed indication GC Cell

Biotech Distilled coverage (5)

2026-05-19 UPDATE: Artiva (ARTV) - The CFO Walks. Ten Days After the Raise. 🔒 Paid
2026-05-09 UPDATE: Artiva (ARTV) - The Watch List Pays Off 🔒 Paid
2026-03-14 UPDATE: Artiva (ARTV) - The Autoimmune Pivot is Complete... 🔒 Paid
2026-02-28 UPDATE: Artiva (ARTV) - The CFO Red Flag is Gone... 🔒 Paid
2025-12-17 Artiva Biotherapeutics (ARTV): Scientific Due Diligence for AlloNK and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.